Key result
The Prostate Health Index (PHI) demonstrated significantly higher accuracy for predicting prostate cancer compared to urinary PCA3 (AUC 0.70 vs 0.59; p=0.043).
Why the study?
Does the Prostate Health Index (PHI) improve the accuracy of predicting prostate cancer compared to urinary PCA3 in patients undergoing prostate biopsy?
Observational (n=211)
Does the Prostate Health Index (PHI) improve the accuracy of predicting prostate cancer compared to urinary PCA3 in patients undergoing prostate biopsy?
Absolute Event Rate: 0.7% vs 0.59%
p-value: p=0.043
PHI provides significantly higher diagnostic accuracy for predicting prostate cancer at biopsy compared to PCA3, total PSA, and free-to-total PSA.
No takes yet. Share an insight, caveat, or question.
PHI may improve prostate cancer prediction over PCA3; leaves open prospective validation before clinical adoption.
Scattoni et al. (2013) conducted an observational in Prostate cancer (n=211). Prostate Health Index (PHI) vs. Urinary PCA3 was evaluated on Accuracy for predicting prostate cancer (AUC) (p=0.043). The Prostate Health Index (PHI) demonstrated significantly higher accuracy for predicting prostate cancer compared to urinary PCA3 (AUC 0.70 vs 0.59; p=0.043).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: